Alendronate induced subacute cutaneous lupus erythematosus successfully treated with intravenous immunoglobulin

Uzuncakmak T. K., Bayazit S., Askin O., Engin B., Ugurlu S., Sar M., ...More

DERMATOLOGIC THERAPY, vol.33, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33
  • Publication Date: 2020
  • Doi Number: 10.1111/dth.14477
  • Journal Name: DERMATOLOGIC THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Istanbul University Affiliated: Yes

Abstract

The subacute cutaneous lupus erythematosus (SCLE) is a distinct subtype of lupus erythematosus (LE) representing specific clinical and serological features. Almost 20%-30% of the cases with SCLE are predicted to associated with medications. Thiazide diuretics, terbinafine, antiepileptic, and proton pump inhibitors are the best-known drugs to induce drug-related SCLE. Herein we want to present a 65-year-old female with alendronate induced SCLE, resistant to classical therapies, and respond well to intravenous immunoglobulin (IVIG), suggesting that IVIG could be an alternative treatment in patients resistant to classical treatment protocols.